Document is current
Any future updates will be listed below
-
Authors
Chang, Liang
Shaw, Katharin
Vazquez, Francisca
Sellers, William R. https://orcid.org/0000-0002-3539-9803
- License Information
-
More Information
Article History
Accepted: 18 March 2026
First Online: 23 April 2026
Competing interests
: L.C. is an employee of Aditum Bio. F.V. receives research support from the Dependency Map Consortium, Riva Therapeutics, Bristol-Myers Squibb, Merck, Illumina and Deerfield Management; is on the scientific advisory board of GSK; is a consultant and holds equity in Riva Therapeutics; and is a cofounder and holds equity in Jumble Therapeutics. W.R.S. is a board or scientific advisory board member and/or holds equity in Atavistik Bio, CJ Bioscience, Delphia Therapeutics, Ideaya Biosciences, Pierre Fabre, RedRidge Bio and Scorpion Therapeutics, has consulted for Array, Astex, Epidarex Capital, Ipsen, Merck Pharmaceuticals, Sanofi and Servier and receives or received research funding from Bayer Pharmaceutical, Bristol-Myers Squibb, Boehringer-Ingelheim, Ideaya Biosciences, Calico Biosciences, Novartis Pharmaceuticals and Servier Pharmaceuticals. W.R.S. is a co-patent holder on EGFR mutation diagnostic patents. K.S. declares no competing interests.
